John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Sleep disorders, immunity and inflammatory bowel diseases Volume 29, issue 7, September 2022

Figures

  • Figure 1
  • Figure 2
  • Figure 3
  • Figure 4
  • Figure 5
Authors
1 Hospices civils de Lyon, Service d’hépato-gastroentérologie, 165, chemin du Grand Revoyet, 69310 Pierre-Bénite
2 Inserm U1111, CIRI, 46 allée d’Italie, 69007 Lyon
3 Hospices civils de Lyon, Service de médecine du sommeil et des maladies respiratoires, 103, grande rue de la Croix-Rousse, 69004 Lyon
4 Centre de recherche en neurosciences de Lyon, Inserm U1028/CNRS UMR5292, Centre hosptalier Le Vinatier, 95, boulevard Pinel, 69678 Bron
Correspondance : S. Nancey

Sleep disorders affect 47% to 82% of Inflammatory Bowel Disease (IBD) patients and are associated with both the inflammatory activity and the clinical course of the disease. Disease activity and the presence of associated anxiety disorders are the main risk factors for sleep disturbance in IBD patients. However, almost 50% of patients in remission maintain poor sleep quality, suggesting a close relationship between IBD and sleep disturbances that may contribute to the fatigue observed in most of IBD patients. Several studies report a bidirectional link between sleep disturbance and inflammation. In Crohn’s disease, the presence of sleep disorders is an early marker of subclinical inflammation and in patients in remission, poor sleep quality is associated with the risk of relapse at 6 months. Sleep disturbances are important contributors to functional disability in IBD, and their detection and management may improve patient quality of life. The impact of the management of sleep disorder on IBD activity remains to be investigated.